Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the...
Year: 2023
Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
Positive and clinically meaningful pivotal clinical results announced in 2022 in both metastatic and locally advanced indicationsWALTHAM, Mass., Jan. 04,...
Helsinn publishes results from a secondary analysis of a Phase 3 trial in patients with CINV Helsinn publishes results from a secondary analysis of a Phase 3 trial in patients with CINV
Helsinn publishes results from a secondary analysis of a Phase 3 trial in patients with CINV in The Oncologist Lugano,...
Jasper Therapeutics Announces European Union Orphan Drug Designation for Briquilimab as a Conditioning Treatment for Patients Prior to Receiving a Stem Cell Transplant
REDWOOD CITY, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on transforming...
Elixirgen Therapeutics to Attend the 2023 Biotech Showcase Conference
BALTIMORE, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and...
Akari Therapeutics to Present at Biotech Showcase™ 2023
NEW YORK and LONDON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing...
Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a...
Cidara Therapeutics Nominates First Oncology Clinical Development Candidate from its Cloudbreak® Platform
CBO-212 is a first-in-class inhibitor of CD73 cancer immunotherapy targetSAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc....
Erasca to Present at the 41st Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on...
Tenax Therapeutics Announces Reverse Stock Split
MORRISVILLE, N.C., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying,...
Accolade Announces Participation in 25th Annual Needham Growth Conference
SEATTLE, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will participate in the 25th...
Collegium Provides 2023 Financial Guidance
– Product Revenues, Net Expected in the Range of $565.0 Million to $580.0 Million – – Adjusted Operating Expenses* Expected...
Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to its Board of Directors
CHARLOTTESVILLE, Va. and CARMEL, Ind., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”),...
Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and...
TeraImmune Extends CRADA for Development of Treg Expansion for Clinical Use
GERMANTOWN, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- TeraImmune, Inc., a biotechnology company focused on the discovery and development of...
Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer
WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the...
Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for...
IGC Receives No Objection Letter from Health Canada
POTOMAC, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or...
Online Enrollment Now Open for Physicians Requesting Expanded Access to Ascendis Pharma’s TransCon™ PTH for Eligible U.S. Adult Patients with Hypoparathyroidism
- The Expanded Access Program (EAP) allows physicians to request access to TransCon PTH, the company’s investigational parathyroid hormone replacement...
LifeMD Appoints Jessica Friedeman as Chief Marketing Officer to Support the Company’s Rapid Expansion into Virtual Primary Care
NEW YORK, Jan. 04, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced the...